Summary
The product NPP 200 mg (Nandrolone Phenylpropionate), manufactured by Olympian Pharmaceutical, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number 0069, was submitted by Olympian Pharmaceutical and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Nandrolone Phenylpropionate, with a concentration of 132.93 mg/ml, which is 33.54% below the labeled claim of 200 mg/ml.
The testing process began on 24 October 2024, with the sample received on 30 October 2024, and analysis completed on 05 November 2024. The results confirm the presence of the active ingredient, but the measured concentration is significantly lower than the stated amount on the label. Independent third-party testing remains essential to validate these findings and ensure consistency across different batches. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Olympian Pharmaceutical
- Product Name: NPP 200 mg
- Active Ingredient: Nandrolone Phenylpropionate
- Batch Number: 0069
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #51782
- Testing Ordered: 24 October 2024
- Sample Received: 30 October 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Olympian Pharmaceutical (Manufacturer)
- Analysis Paid For By: Olympian Pharmaceutical (Manufacturer)
Testing Results
- Specification: 200 mg/ml (as stated on the label)
- Measured Concentration: 132.93 mg/ml
- Accuracy: 66.46% (33.54% below the label claim)
Verification Details
Verification URL: https://janoshik.com/tests/51782_6NNSELKVSAF2
Evaluation of Manufacturer-Submitted Testing
This analysis reveals that NPP 200 mg is significantly underdosed, with a measured concentration of 132.93 mg/ml, which is 33.54% below the labeled claim. This deviation indicates potential issues in manufacturing consistency and quality control. Since Olympian Pharmaceutical submitted and funded the test, independent validation through third-party testing remains crucial to confirm product uniformity across different batches. The large discrepancy suggests that additional scrutiny is necessary to ensure accuracy in dosing.
Conclusion
The analysis confirms that NPP 200 mg is significantly underdosed, with a measured concentration of 132.93 mg/ml, which is 33.54% below the labeled claim. The presence of the active ingredient is verified, but the lower-than-expected concentration raises concerns about product reliability. This underscores the importance of continued testing to ensure accurate dosing and quality control. This report is provided as an educational and harm reduction resource, helping consumers make informed choices regarding steroid-based products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it provides useful data when critically assessed alongside third-party independent results. Readers are encouraged to use this information responsibly.
